Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
10 studies found for:    parp prostate cancer | Open Studies
Show Display Options
RSS Create an RSS feed from your search for:
parp prostate cancer | Open Studies
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Studying the Effects of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Radical Prostatectomy
Condition: Prostate Cancer
Interventions: Drug: Olaparib;   Drug: Degarelix
2 Not yet recruiting Nivolumab in Prostate Cancer With Mutations in DNA Repair Defects (ImmunoProst Trial)
Condition: Prostate Cancer
Intervention: Drug: Nivolumab
3 Not yet recruiting Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Condition: Prostate
Intervention: Drug: Olaparib
4 Recruiting Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Castration-Resistant Prostate Carcinoma;   Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation;   Prostate Carcinoma Metastatic in the Bone;   Prostate Small Cell Carcinoma;   Stage IV Prostate Adenocarcinoma
Interventions: Drug: Cediranib;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib
5 Recruiting A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Condition: Metastatic Castration Resistant Prostate Cancer
Intervention: Drug: Rucaparib
6 Recruiting A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Condition: Metastatic Castration Resistant Prostate Cancer
Interventions: Drug: Rucaparib;   Drug: Abiraterone acetate or Enzalutamide or Docetaxel
7 Recruiting An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
Condition: Prostatic Neoplasms
Intervention: Drug: Niraparib
8 Recruiting Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Conditions: Prostate Cancer Metastatic Castration-Resistant;   Abnormal DNA Repair;   Metastatic Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Drug: Olaparib;   Drug: Abiraterone Acetate;   Drug: Prednisone
9 Recruiting Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
Conditions: Lung Cancer;   Breast Cancer;   Ovarian Cancer;   Colorectal Cancer;   Prostate Cancer;   Triple Negative Breast Cancer
Interventions: Drug: Olaparib;   Drug: Cediranib;   Drug: MEDI4736
10 Recruiting A Study of SC10914 in Patients With Advanced Solid Tumors
Condition: Advanced Solid Tumors
Intervention: Drug: SC10914

Study has passed its completion date and status has not been verified in more than two years.